Dec 18 $6 / $7 Bull Call Spread
Buy 4x $6C · Sell 4x $7C · 32d
Updated Nov 19, 2026 8:30 PM ET · Prev Close $5.50
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 1.3% on average.
Compare deploying $581 for 100 EBS shares against capped-risk 5-day option structures priced at 78.8% ATM implied volatility.
Buy 4x $6C · Sell 4x $7C · 32d
Sell 2x $5P · Buy 2x $6/$7C · 32d
Our options desk modeled ATM Call Rebound / Continuation, ATM Put Downside Positioning structures for the Dec 18 expiration cycle, plus live unusual contract strike sweeps and full factor sub-scores.
To support its efforts around health preparedness, Emergent will use Asimov s CHO Edge System to help develop novel medical countermeasuresBOSTON and Gaithersburg, Md., Nov. 16, 2026 Globe Newswire -- Asimov, the company
Gaithersburg, Md., November 10, 2026--Emergent BioSolutions Inc. NYSE Ebs announced today that members of the company s senior management team will participate in the Jefferies Global Healthcare Conference in London, Nov
Emergent BioSolutions Inc EBS posted a soft 110 million third quarter on MCM delivery timing, yet raised full-year gross margin guidance by 300 basis points and cut gross debt to 514 million.
Gaithersburg, Md., November 04, 2026--Emergent BioSolutions Inc. NYSE Ebs today announced that it has received a modification exercising an option period under its existing delivery order valued at up to 22.3 million to
Watch for breakdown below $5.14
Sessions in the past year where EBS moved >3.0% down:
One bullish trader on StockTwits expressed confidence in adding to their $EBS position.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthr...
Receive an email alert when EBS triggers an unusual volume breakout, options sweep, or rating shift.
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 1.3% on average.
Today's session carries a 65% catalyst conviction score on 0.55x relative volume (low participation). Our multi-factor model currently rates EBS as HOLD. Review full valuation, quality, and timing signals on the EBS Buy or Sell Decision Brief →
At $5.15, EBS's modeled 1-to-3 session range is $4.99 – $5.25, with a key inflection level at $4.89 (support). Compare current price against multi-year cash flow projections in the EBS Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
RSI at 29.2 indicates oversold conditions — watch for mean-reversion support. EBS trades at $5.15 relative to its 20-day SMA ($6.14) and 50-day SMA ($6.47), reflecting a bearish moving-average structure.
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.